THE PDGFR/SRC SIGNALING PATHWAY-TARGETED THERAPY WITH NOVEL TUSC2-NANOPARTICLES AND TYROSINE KINASE INHIBITORS FOR HUMAN LUNG CANCER

被引：0
|
作者：
Wu, Quanglin [1 ]
Liu, Qing [1 ]
Sakai, Ryo [1 ]
Hangauer, David [2 ]
Roth, Jack [1 ]
Ji, Lin [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] SUNY Buffalo, Buffalo, NY 14260 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
Lung cancer; PDGFR-Src signaling pathway; TUSC2 (FUS1)-nanoparticle; PDGFR and Src kinase inhibitors;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.05-003
引用
收藏
页码：S459 / S459
页数：1
相关论文
共 50 条
  • [1] The Src-PI3K-Akt and apoptosis signaling pathway-targeted therapy with novel pro-apoptotic FUS1-nanoparticles and Src kinase inhibitors for lung cancer
    Wu, Guanglin
    Sakai, Ryo
    Xu, Kai
    Hangauer, David
    Roth, Jack
    Ji, Lin
    CANCER RESEARCH, 2009, 69
  • [2] The Src-PI3K-Akt and apoptosis signaling pathway-targeted therapy with novel pro-apoptotic FUS1-nanoparticles and Src kinase inhibitors for lung cancer
    Ji Lin
    Wu Guanglin
    Sakai, Ryo
    Roth, Jack A.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S601 - S601
  • [3] Preclinical Modeling of Pathway-Targeted Therapy of Human Lung Cancer in the Mouse
    Vaishnavi, Aria
    Kinsey, Conan G.
    Mcmahon, Martin
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2024, 14 (01):
  • [4] Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma
    Bolcaen, Julie
    Nair, Shankari
    Driver, Cathryn H. S.
    Boshomane, Tebatso M. G.
    Ebenhan, Thomas
    Vandevoorde, Charlot
    PHARMACEUTICALS, 2021, 14 (07)
  • [5] A novel tyrosine kinase signaling pathway in human basal breast cancer
    Daly, Roger J.
    Hochgraefe, Falko
    Croucher, David R.
    Zhang, Luxi
    Rickwood, Danny
    Browne, Brigid C.
    Tactacan, Carole
    Raftery, Mark
    CANCER RESEARCH, 2011, 71
  • [6] Tyrosine kinase inhibitors targeted therapy and the AKT-m-TOR pathway in kidney cancer tissues
    Spirina, L. V.
    Usynin, E.
    Kondakova, I.
    Yurmazov, Z.
    Slonimskaya, E.
    Kolegova, E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Preclinical Modeling of Pathway-Targeted Therapy of Human Lung Cancer in the Mouse (Oct, 10.1101/cshperspect.a041385, 2023)
    Vaishnavi, Aria
    Kinsey, Conan G.
    Mcmahon, Martin
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2025, 15 (01):
  • [8] AN EFFECTIVE DNA DAMAGE/REPAIR SIGNALING PATHWAY-TARGETED THERAPY FOR LUNG CANCER COMBINING A NOVEL DUAL-FUNCTIONAL DNA-ALKYLATING/HDAC INHIBITOR WITH TUMOR SUPPRESSOR GENE NANOPARTICLES
    Ji, Lin
    Lin, Jing
    Xu, Kai
    Yan, Shaoyu
    Chen, Yi
    Roth, Jack A.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S591 - S592
  • [9] Multi-targeted tyrosine kinase inhibitors for the treatment of nonsmall cell lung cancer: an era of individualized therapy
    Zhou, Caicun
    TRANSLATIONAL LUNG CANCER RESEARCH, 2012, 1 (01) : 72 - 77
  • [10] HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
    Nielsen, Dorte Lisbet
    Andersson, Michael
    Kamby, Claus
    CANCER TREATMENT REVIEWS, 2009, 35 (02) : 121 - 136
12345